Pozen Inc. (POZN)

[surf1944]

8:02AM POZEN announces preliminary injunction ordered in POZEN Treximet patent litigation (POZN) 5.82 : Co announced that the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction ordering Par Pharmaceutical (PRX) not to make, use, sell, offer to sell, or import into the United States a generic version of sumatriptan/naproxen sodium that competes with Treximet sold by GlaxoSmithKline (GSK) in the US under an exclusive license from the co. The order was entered in connection with the patent infringement lawsuit pending among the co and Par, Alphapharm, Teva Pharmaceuticals (TEVA), and Dr. Reddy's (RDY) relating to the submission to the FDA of Abbreviated New Drug Applications (ANDAs) by the four generic companies and the generic companies' plans to market sumatriptan and naproxen sodium products pursuant to such ANDAs, which the cocontends infringe three of its patents covering Treximet.